New analyses examine Afrezza across pediatric A1c and efficacy, patient treatment satisfaction, use with AID algorithms and ...

Globally and in India, T2DM prevalence continues to rise, with obesity as one of its most important clinical drivers, reported in nearly 60-90% of Indian patients with T2DM. GLP-1 receptor ...

Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline Initiated five ...

A report analyzed the frequency and magnitude of savings from purchasing generic prescriptions through the Mark Cuban Cost Plus Drug Company (MCCPDC) compared with cost sharing under ...

D&D Pharmatech, Inc. (D&D) (KOSDAQ: 347850), a clinical-stage biotechnology company developing breakthrough treatments for liver and metabolic diseases, today announced positive top-line 48-week ...

Engineers must carefully manage power, protection, and sensing interactions at every design level to achieve reliable, always-on operation in a body-worn form factor. (Source: Getty Images) Continuous ...

Afrezza is the only ultra-rapid-acting inhaled insulin approved by the FDA to improve glycemic control in children and adults. ・Approval is supported by results from the Phase 3 INHALE-1 study in ...

When researchers pooled data from six major semaglutide weight-loss trials and zeroed in on participants aged 65 and older, ...

Doctronic reports that Foundayo, an oral GLP-1 for diabetes, shows promise but lacks long-term safety data beyond 68 weeks; ongoing studies are needed.

Kailera Therapeutics is advancing a pipeline of weight loss medicines that mirror that of Eli Lilly’s: an injectable GLP-1/GIP dual agonist like Zepbound, an oral GLP-1 like Foundayo and a triple-G ...

"Hacks" Season 5 concluded on May 28, revealing what's next for Jean Smart's Deborah Vance and Hannah Einbinder's Ava Daniels ...

Jurupa Valley senior AB Hernandez placed third in the long jump alongside a cisgender girl also awarded a bronze medal at the CIF state championship meet.